uniQure N.V.(QURE)

Sector:

Healthcare

Description:

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Current Price

$20.05

RSI

49.18

Market Capitalization:

889.7M

Beta:

0.993

Volume:

458,752

Analyst Target Price:

$ 49.75

Economiic Fair Price:


October 24, 2022
August 08, 2022
Q2
N/A
N/A
N/A
N/A
N/A
500.5M
139.1M
7.6
-184.10 %
1.335
-0.204

68.81 %
13.50 %
-31.89 %
-99.89 %
-109.78 %
-104.89 %

$ 524M
1296.82 %
$ 37.5M
415.23 %
$ 7.3M
-35.48 %
$ 11.3M
-13.91 %
$ 13.1M
-47.78 %
$ 25.1M

$ 270.5M
287.46 %
$ -144.3M
-37.01 %
$ -105.3M
-31.20 %
$ -80.3M
-14.93 %
$ -69.9M
21.83 %
$ -89.4M

$ 332.8M
335.29 %
$ -141.4M
-13.88 %
$ -124.2M
-49.51 %
$ -83.1M
-4.55 %
$ -79.5M
-10.01 %
$ -72.2M

News

Press Releases

Notable Dates